Targeted therapy for acute myeloid leukaemia (AML)
Targeted therapy uses drugs that attack specific features of cancer cells, known as molecular targets, to stop the cancer growing and spreading. There are now a few targeted therapy drugs for AML with changes in particular genes. However, these drugs are not yet subsidised by the government through the Pharmaceutical Benefits Scheme (PBS), so they are available only through compassionate access schemes or clinical trials.
For more on this, see Targeted Therapy.
|A new type of drug treatment called immunotherapy uses the body’s own immune system to fight cancer. This is still experimental for AML, but it is being tested in some clinical trials. Ask your doctor if there are any recent advances that might be relevant for you.|
Dr Anoop Enjeti, Senior Staff Specialist Haematologist, Calvary Mater Newcastle, and Conjoint Senior Lecturer, The University of Newcastle; Ray Araullo, Deputy Head, Social Work Department, Royal North Shore Hospital; Shehaan Fernando, Consumer; Narelle Greentree, Clinical Nurse Specialist, Hunter Haematology Unit, Calvary Mater Newcastle; Yvonne King, 13 11 20 Consultant, Cancer Council NSW; Karen Maddock, Haematology Clinical Nurse Consultant, Westmead Hospital; Melanie Sexton, Consumer; Dr Jonathan Sillar, Haematology Registrar, Calvary Mater Newcastle, and Conjoint Fellow, The University of Newcastle.
View the Cancer Council NSW editorial policy.
The information on this page is also available for download.